Worldwide Market Reports added Latest Research Report titled “Lysosomal Alpha Glucosidase Market - Size, Share, Outlook, and Forecast till 2026”
Lysosomal alpha-glucosidase is an enzyme that is encoded by the GAA gene in humans. It is also called as α-1, 4-glucosidase and acid maltase. Any errors in this gene would lead to glycogen storage disease type II and Pompe disease. Acid alpha-glucosidase essential for the degradation of glycogen to glucose in lysosomes is encoded by this gene. By proteolytic processing, different forms of acid alpha-glucosidase can be obtained. Three transcript variants encoding the same protein have been found for this gene. Lysosomal alpha-glucosidase is used for the treatment of glycogen storage disease and Pompe disease.
Increasing prevalence of diseases such as glycogen storage disease and Pompe disease and increasing number of population are major factors driving growth of lysosomal alpha glucosidase market.
Request Sample of Copy of the Business Report: https://www.worldwidemarketreports.com/sample/196805
Key Developments in Lysosomal Alpha Glucosidase Market
Key players are adopting various strategies such as mergers, acquisitions, new product launches, expansions, collaborations, partnerships, approvals, and joint ventures to retain its position in the lysosomal alpha glucosidase market. On March 22, 2018, Amicus Therapeutics announced that Japan's Ministry of Health, Labor and Welfare (MHLW) approved the oral small molecule pharmacological chaperone Galafold® capsules for the treatment of Fabry disease.
On February 27, 2018, Amicus Therapeutics launched Healing Beyond Disease™ initiatives to change lives of people living with rare diseases. Moreover, on April 30, 2018, the U.S. Food and Drug Administration (FDA) accepted priority review of cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for surgery.
Request for Complete TOC before buying this exclusive Report by WMR: https://www.worldwidemarketreports.com/toc/196805
Moreover, on April 10, 2018, precision nozzles manufactured by Lechler fulfilled the Council In June 2017, Sarepta Therapeutics signed a collaboration with Genethon, a non-profit R&D organization dedicated to the development of biotherapies for orphan genetic diseases from research to clinical validation. Furthermore, on April 26, 2018, JCR Pharmaceuticals announced the decision of the company to construct the Second Clinical Trial Material Manufacturing Center.
Some of the key players operating in the lysosomal alpha glucosidase market include Amicus Therapeutics Inc, Audentes Therapeutics Inc, Etubics Corp, Genzyme Corp, greenovation Biotech GmbH, Huons Co Ltd, JCR Pharmaceuticals Co Ltd, Oxyrane Belgium NV, Pharming Group NV, and Sarepta Therapeutics Inc among others.
Browse more detail information about This Report: https://www.worldwidemarketreports.com/market-insights/lysosomal-alpha-glucosidase-market
** If you have any special requirements, please let us know and we will offer you the report as you want.
Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domainsv and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.
Worldwide Market Reports
1001 4th Ave,
Seattle, WA 98154,
Tel: +1 415 871 0703
Email: [email protected]
Our latest New Site: https://www.industrychronicle.com/